Lisata Therapeutics Share Price Today

Lisata Therapeutics appoints Jeffrey Farrow to board of directors

Jeffrey Farrow appointed to Lisata Therapeutics Board effective October 13, 2026. Board size increases from seven to eight members with new independent director. Farrow joins Audit Committee; brings CFO experience from Tarsus and Global Blood Therapeutics.

Marea Therapeutics doses first patient in Phase 2 acromegaly trial

Marea Therapeutics dosed the first patient in its Phase 2 clinical trial for MAR002. MAR002 is a first-in-class allosteric monoclonal antibody targeting the growth hormone receptor. Phase 1 data showed deep IGF-1 suppression with potential bi-weekly dosing intervals. Current standard of care requires daily subcutaneous injections for acromegaly management.

Lisata acquires Marea, secures $225 million financing for pipeline

Lisata acquires Marea Therapeutics to focus on cardioendocrine diseases. Company secures $225 million in oversubscribed private placement. Marea holders will own 59.54% of combined entity; Lisata holders 2.39%. Funds will advance MAR001/005 and MAR002 through Phase 2 trials. Lisata cut 72% of staff after terminating prior merger with Kuva Labs.

Lisata Therapeutics sues Kuva Labs, cuts 72% of staff

Lisata Therapeutics sues Kuva Labs for breach of merger agreement, seeking $2M fee. The company cuts 72% of its workforce to preserve cash while evaluating strategic alternatives like acquisition or liquidation.

Johnson Fistel investigates Lisata Therapeutics over acquisition financing

Johnson Fistel, PLLP has launched an investigation into Lisata Therapeutics, Inc. concerning disclosures about the financing of its acquisition by Kuva Labs, Inc. The investigation follows a series of amendments and delays regarding the tender offer, which ultimately commenced without committed financing. The firm is evaluating potential losses for investors under federal securities laws.

Lisata Therapeutics accepts $4.00 per share tender offer from Kuva Labs

Lisata Therapeutics, Inc. announced that Kuva Acquisition Corp., a wholly owned subsidiary of Kuva Labs Inc., has commenced a tender offer to acquire all outstanding shares for $4.00 per share in cash at closing, plus one non-tradeable CVR. The CVR provides for additional payments of $1.25 upon Phase 2a trial milestones and $1.75 upon NDA filing for certepetide. The Board unanimously recommends the offer, which is expected to close in Q3 2026, pending regulatory approvals and share tender thresholds.